The M235T polymorphism of human angiotensinogen is associated with essential and pregnancy-induced hypertension. A covalent complex is formed between angiotensinogen and the proform of the eosinophil major basic protein (proMBP) during pregnancy. Angiotensinogen is the specific substrate of renin in the renin-angiotensin system. Angiotensinogen belongs to the serine protease inhibitor (serpin) superfamily (1), although it has probably lost this activity (2). Linkage and case-control studies have shown the potential role of the human angiotensinogen gene (hAGT) 1 as a susceptibility gene to develop hypertension (reviewed in Ref.
(72%) than for Thr 235 (58%) angiotensinogen. These data suggest a new pathophysiological explanation for the genetic association between M235T angiotensinogen polymorphism and pregnancy-induced hypertension.
Angiotensinogen is the specific substrate of renin in the renin-angiotensin system. Angiotensinogen belongs to the serine protease inhibitor (serpin) superfamily (1) , although it has probably lost this activity (2) . Linkage and case-control studies have shown the potential role of the human angiotensinogen gene (hAGT) 1 as a susceptibility gene to develop hypertension (reviewed in Ref. 3) . The M235T angiotensinogen polymorphism, which is in strong linkage disequilibrium with the G-6A substitution in the promoter (4) , has been associated with essential (5) and pregnancy-induced (6) hypertension.
Purified plasma angiotensinogen is a heterogeneous protein which migrates at around 60 kDa on SDS-polyacrylamide gel electrophoresis (SDS-PAGE). In addition to this classical monomeric form of angiotensinogen, a high molecular weight form (HMW) has been described in human species (Ref. 7 ; for a review, see Ref. 8) which is a major component of the placentaspecific renin-angiotensin system, predominant in amniotic fluid (9, 10) and in extracts of placental tissue (11) . The plasma of men and menstruating women contains around 5% of the total angiotensinogen as HMW angiotensinogen (12) (13) (14) and this can reach 9.6% in women on estrogen contraceptive (12) . The percentage of the HMW form increases to 16% in normal pregnancy, and can reach 25-28% in pregnancy-induced hypertension (12) . Kinetic studies have shown that renin produces angiotensin I (Ang I) 1.9 times faster from monomeric than from HMW angiotensinogen at physiological pH (15) . Previous studies using disulfide bridge reduction (16) and immunoreactivity analysis (17) have suggested that the HMW angiotensinogen could be a covalent complex of monomeric angiotensinogen with other angiotensinogen molecules, or other proteins. Recently, the purification of the proform of the human eosinophil major basic protein (proMBP) from the serum of pregnant women revealed two circulating heterodimeric complexes of angiotensinogen and proMBP covalently linked by disulfide bonds. These complexes were a 2:2 complex of angiotensinogen and proMBP, or a 2:2:2 complex of angiotensinogen, proMBP and complement C3dg (18) . They could contribute, at least in part, to HMW angiotensinogen.
The sequence of human angiotensinogen contains four cysteine residues at amino acid positions 18, 138, 232, and 308. Only the Cys 18 and Cys 138 are present in all four mammalian species cloned so far (19 -22) . Nothing is known about the possible presence of a disulfide bond in angiotensinogen, and consequently which cysteine could interact with proMBP. This study was done to identify cysteine residue of human angiotensinogen involved in a disulfide bridge with proMBP and to study the formation and the function of the angiotensinogen⅐proMBP complex in vitro. We carried out sitedirected mutagenesis of single cysteine residues and combinations of them in 8 mutants of human angiotensinogen. Analysis of these mutants, and of a fully deglycosylated human angiotensinogen, indicated a disulfide bond between Cys 18 and Cys 138 . We produced a recombinant angiotensinogen⅐proMBP complex and demonstrated that Cys 232 is needed for the formation of this complex which is influenced by the M235T substitution. Finally, human renin hydrolyzed this complex 7 times slower than the monomeric recombinant human angiotensinogen.
EXPERIMENTAL PROCEDURES
Materials-Pure human recombinant renin was a gift from Hoffman-La Roche (Basel, Switzerland). The full-length cDNA of human * This work was supported by grants from INSERM and Hoffmann-La Roche. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ 1 The abbreviations used are: hAGT, human angiotensinogen; PAGE, polyacrylamide electrophoresis gel; HMW, high molecular weight; Ang I, angiotensin I; proMBP, proform of human eosinophil major basic protein; MBP, human eosinophil granule major basic protein; CHO, Chinese hamster ovary; DTT, dithiothreitol; MALDI-MS, matrix-assisted laser desorption ionization-mass spectrometry.
eosinophil granule MBP cloned into the EcoRI site of pUC 12 was kindly provided by Dr. Gerald Gleich (Mayo Clinic, Rochester, MN) and the J163-15E specific proMBP monoclonal antibody was a gift from Dr. Lars Sottrup-Jensen (University of Aarhus, Aarhus, Denmark). Cell culture reagents and fetal calf serum were obtained from BoehringerMannheim (Meylan, France). Chemicals were purchased from Sigma and chromatography columns from Pharmacia Fine Chemicals (Uppsala, Sweden). Molecular masses were estimated by comparison with prestained SDS-PAGE molecular mass markers from Bio-Rad or with 14 C-methylated proteins from Amersham. Nondenaturing Purification of Human Recombinant Angiotensinogen-Large scale production and non-denaturing purification methods of recombinant wild-type human angiotensinogen will be described elsewhere. 2 Briefly, pure Chinese hamster ovary (CHO) cell line overproducing wild-type human angiotensinogen (23) was expanded into cell factories and depleted into serum-free medium in order to produce 50 to 80 mg of recombinant protein. The non-denaturing purification of recombinant angiotensinogen was performed by a three-step procedure which included the following: chromatography on phenyl-Sepharose, concanavalin A-Sepharose, and Mono Q. The final product exhibited the theoretical specific activity: 26 g of Ang I/mg of protein.
Iodo (24) was analyzed by SDS-PAGE in non-reducing and reducing conditions (ϩdithiothreitol (DTT) 10 mM) after denaturation (4 min at 94°C). The gel was immediately stained using the colloidal blue stain kit (Novex). A piece of gel containing a 48-kDa band (which was not present in the untransfected CHO cell supernatant used as a control) was excised, digested with trypsin, and analyzed by matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS) according to Ref.
25.
Reduction of Angiotensinogen-The disulfide bond in purified recombinant angiotensinogen (10 g) was reduced by incubating with 100 mM sodium acetate, pH 6.0, containing 1% (v/v) glycerol and 10 Ϫ2 to 10 mM DTT at 50°C for 10 min. The newly generated free sulfhydryl groups were alkylated by adding 10 mM iodoacetic acid for 30 min at room temperature. Traces of reducing and alkylating agents were removed by extensive dialysis. Samples were analyzed by Western blotting for their reaction with an antibody directed against the NH 2 -terminal part of Ang I called N1345 (diluted 1/1000). This anti-Ang I antibody was made using a synthetic peptide containing the NH 2 -terminal part of Ang I sequence (hAGT(1-6-Cys 7 ): NH 2 -Asp 1 -Arg-Val-Tyr-Ile-His 6 -Cys-C-OOH). The cysteine residue was added to direct the antibody against the NH 2 -terminal region. The peptide was covalently S-S coupled to keyhole limpel hemocyanin as carrier protein and injected into rabbits. The antibodies against this peptide were characterized by enzymelinked immunosorbent assay (specific titer: 1/4000) (ANAWA Trading SA, Biomedicals Services and Products, Zurich). The specificity of the reaction against whole angiotensinogen was checked by negative controls with preimmune serum from the same rabbit, competition with peptide concentrations of 10 nM to 1 M, and reaction with the des-Ang I-angiotensinogen. Samples were also analyzed for their ability to generate Ang I after hydrolysis with human renin (1.25 nM) by enzymatic assay (23) . Results are expressed as the ratio between the amount of Ang I generated in each reduced condition and the amount of Ang I generated without DTT and with alkylating agent (100%).
Site-directed Mutagenesis of hAGT cDNA-The human angiotensinogen cDNA (26) codes for a Met in position 235 and contains four cysteine residues at positions 18, 138, 232, and 308. It has been subcloned into the eucaryotic expression vector pECE (23) . Site-directed mutagenesis of Met 235 to Thr and of each Cys (at positions 18, 138, 232, and 308) to Ala was performed with the same procedure previously described (24) . One of the following antisense mutagenesis oligonucleotide was used: (Met 235 -Thr) 5Ј-GTCCACACTGGCTCCCGTCAGGGAGCAGCCAGT-3Ј; (Cys 18 -Ala) 5Ј-CGCGAGCTGCTCAGCGGTACTCTCATT-3Ј; (Cys 138 -Ala) 5Ј-CAGCCGGGAGGTGGCGTTCTTGTCCTT-3Ј; (Cys 232 -Ala) 5Ј-T-CCCATCAGGGAGGCGCCAGTCTTGGA-3Ј; (Cys 308 -Ala) 5Ј-GATCAG-CAGCAGGGCGGCGCTCTCAGT-3Ј. Five single mutant hAGT cDNAs were produced: M235T, C18A, C138A, C232A, and C308A and used for a second and third round of mutagenesis to obtain the following double mutants: C232A/M235T (using oligonucleotide: 5Ј-TCCCGTCAGGGA-GGCGCCAGTCTTGGA-3Ј), C18A/C138A and C18A/C308A and the triple mutant: C18A/C138A/C308A (see Fig. 3A) .
Production of Mutant Human Angiotensinogen Proteins in COS-7 and CHO-K1 Cells-The eight mutant hAGT cDNAs and the wild-type hAGT cDNA were transiently transfected into COS-7 cells using the DEAE-dextran method (27) . The cells were transferred to serum-free medium (Dulbecco's modified Eagles's medium) 2 days after transfection and incubated for 48 h. The resulting supernatants containing recombinant proteins were analyzed on 9% SDS-PAGE with or without 2.5% ␤-mercaptoethanol and Western blotting (24) . Angiotensinogen recombinants were detected with the anti-human angiotensinogen polyclonal antibody:HCL (diluted 1:6000) (28) . Pure CHO-K1 cell lines overproducing Thr 235 and Ala 232 /Thr 235 mutant proteins were established, as reported elsewhere (23) .
Co-transfection and Co-culture Experiments-The MBP cDNA contains the entire sequence (117 amino acids) of human MBP and is translated as a preprotein, which it is co-translationally modified to proMBP and post-translationally modified to MBP (29) . The MBP cDNA was released from pUC 12 by digestion with EcoRI and BglII and inserted into pECE at the same restriction sites, to give the plasmid pE proMBP. This plasmid was used to transiently transfect CHO-K1 cells producing Met 235 or Thr 235 or Ala 232 /Thr 235 angiotensinogen by the calcium phosphate procedure (30), co-transfect COS-7 cells with the cysteine mutant hAGT cDNAs using the DEAE-dextran method, and to establish CHO cell line overproducing proMBP protein. The proMBP protein in the culture medium was checked by Western blotting. The membrane was saturated with 5% (w/v) fat-free milk, incubated overnight with primary antibody J163-15E, an anti-proMBP monoclonal antibody (31), diluted 1:2000 in 50 mM Tris-HCl, pH 9, 500 mM NaCl, and 0.1% (w/v) Tween 20. Antigen-antibody complexes were detected by their alkaline phosphatase activity after biotin-streptavidin enhancement.
The angiotensinogen⅐proMBP complex was produced in vitro by coculture of CHO cells overproducing proMBP (selected by Western blotting) and CHO cells overproducing wild-type (genotype Met 235 , the most common Caucasian variant), or Thr 235 angiotensinogen proteins. The Met 235 or Thr 235 angiotensinogen-producing cells secreted recombinant angiotensinogen with the same production rate: 1.5 g of recombinant protein/ml corresponding to the 24-h production in serum-free medium for 30 ϫ 10 6 cells. To produce large amounts of complex, we have tested several co-culture conditions (10 -90% of proMBP producing or angiotensinogen-producing CHO cells). The selected condition was 10% angiotensinogen-producing cells plus 90% proMBP-producing cells. All the proMBP proteins were complexed with angiotensinogen molecules under these conditions. Complex was produced in 225 cm 2 culture flasks. Cells were plated and grown in Ham's F-12 medium containing 10% fetal calf serum, 10 mM glutamine, 100 units/ml penicillin, 100 g/ml streptomycin, and 500 g/ml Geneticin ® (Life Technologies, Inc.) at 37°C in a 5% CO 2 , 95% air atmosphere for 24 h. The cells were then washed with phosphate-buffered saline and transferred to serum-free medium (UltraCHO. BioWhittaker) for 96 h. Complex was analyzed by Western blotting with human angiotensinogen polyclonal HCL and proMBP monoclonal J163-15E antibodies, to detect angiotensinogen and proMBP, respectively. Untransfected CHO cells were used as negative controls to angiotensinogen-producing cells or proMBP-producing cells. No complex was produced in the absence of proMBP proteins and the production of monomeric angiotensinogen was equivalent: 607 ng/ ml/96 h for Met 235 angiotensinogen and 548 ng/ml/96 h for Thr 235 angiotensinogen. Molecular Sieving-Conditioned medium from CHO cell containing angiotensinogen⅐proMBP complex (angiotensinogen concentration: 3 g/ml) was concentrated 10 times at 4°C by ultrafiltration (30-kDa cut-off membrane, Ultrafree-15 centrifugal filter; Millipore). An aliquot (0.5 ml) was analyzed on a Superose 12 column equilibrated with 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 3 mM EDTA, at 20°C. Fractions (0.4 ml) were collected at a flow rate of 0.4 ml/min. The column was calibrated in the same buffer using ferritin (440,000 Da), catalase (232,000 Da), aldolase (158,000 Da), bovine serum albumin (67,000 Da), chymotrypsinogen A (25,000 Da), and ribonuclease A (13,700 Da) from the HMW/LMW gel filtration calibration kits (Pharmacia Fine Chemicals, Uppsala, Sweeden). Experiments were performed in duplicate for Met 235 angiotensinogen⅐proMBP and for Thr 235 angiotensinogen⅐pro-MBP complexes using medium from two co-culture experiments. Each fraction was analyzed for its angiotensinogen content, measured in triplicate by enzymatic assay using a large excess (12.5 nM) of recombinant human renin and by Western blotting using HCL antibody. The area under the curve of Ang I generation were calculated using FPLC Director Software 1.1 (Pharmacia Fine Chemicals, Uppsala, Sweden).
The Human Renin Concentration Required for Maximal Ang I Production from the Angiotensinogen⅐proMBP Complex-The human renin concentration required for maximal production of Ang I from the angiotensinogen⅐proMBP complex was determined with four renin concentrations and the amount of Ang I peptide produced in 1 h at 37°C at pH 5.7 was measured. Fractions containing angiotensinogen⅐proMBP complex (fractions [23] [24] [25] or monomeric angiotensinogen (fractions 31-33) were pooled. Aliquots (50 l) were incubated in 100 mM citric acid/ Na 2 HPO 4 , 3 mM EDTA buffer, pH 5.7, with 125 pM, 1.25 nM, 12.5 nM, or 125 nM human recombinant renin (32) at 37°C for 60 min. The reaction was stopped by raising the pH to 9.2 with 20 l of 4 M Tris base and chilling. The Ang I generated was measured at each time in triplicate by a specific radioimmunoassay (33) .
The 
RESULTS

Status of Cysteine Residues in Human Angiotensinogen
Identification of Free Cysteine Residues in Human Angiotensinogen-Purified recombinant human angiotensinogen after migration on SDS-PAGE was detected by the anti-human angiotensinogen polyclonal antibody as a large fuzzy band around 60 kDa due to its N-glycosylation (24) (Fig. 1B) . The purity of the preparation was Ն95% as judged by Coomassie Blue staining (Fig. 1C) 14 C]acetic acid gave a radiolabeled heterogeneous 60-kDa band which disappeared when the reaction was performed with excess of cold iodoacetic acid (Fig. 1A) , demonstrating the presence of free cysteine residues in human angiotensinogen.
Location of a 18 -138 Disulfide Bridge by MALDI-MS following
In-gel Tryptic Digestion-As the Asn 14 and Asn 137 , which are close to the cysteine residues, Cys 18 and Cys 138 , are naturally N-glycosylated (24), the wild-type protein is unsuitable for mass spectrometric analysis of generated peptides. We therefore used a fully deglycosylated recombinant angiotensinogen (N-4, in which the Asn at positions 14, 137, 271, and 295 are mutated to Gln) (24) . Recombinant deglycosylated angiotensinogen was run on SDS-PAGE without and with reducing agent (10 mM DTT), and digested with trypsin in-gel. The resulting peptides were analyzed and compared by MALDI-MS (Table I) . A 3083.1-Da peptide was generated in the absence of reducing agent and a peptide with a lower molecular mass (2492.2 Da) was produced in the presence of reducing agent. Their masses fitted exactly with the expected molecular mass of peptides containing Cys 18 Fig. 2A) and for its ability to produce Ang I (Fig. 2B) . The Ang I extremity of angiotensinogen was much better recognized after reduction. Increasing the DTT concentration from 10 Ϫ3 to 10 mM considerably increased recognition of angiotensinogen by the NH 2 -terminal antibody, which suggests that cleavage of Cys 18 -Cys 138 disulfide bond caused a conformational change making the Ang I part of the protein accessible to antibody ( Fig. 2A) . However, high concentration of reducing agent did not change significantly the hydrolysis of the human angiotensiogen by human renin (Fig.  2B) .
Characterization of Cysteine Mutants of hAGT-The role of cysteine residues in the production of angiotensinogen was examined using wild-type hAGT cDNA and 8 cysteine mutant cDNAs to transfect COS-7 cells (Fig. 3A) . The mutant proteins secreted in the medium were studied by Western blotting under reducing (ϩ␤ mercaptoethanol) and non-reducing (Ϫ␤-mercaptoethanol) conditions (Fig. 3B) . Wild-type angiotensinogen produced a fuzzy band between 50 and 70 kDa (16% of the molecular mass is due to the N-glycosylation of the protein; see Ref. 24 ) on SDS-PAGE. Mutation of Cys 18 to Ala (C18A mutant) decreased the molecular weight of the secreted protein by 2-3 kDa, suggesting that the first N-glycosylation site (Asn 14 -Glu 15 -Ser 16 ) was not glycosylated. The C138A mutant protein gave an extra minor band of lower molecular weight (Ϫ2 kDa) after migration in the absence of ␤-mercaptoethanol. This band was also produced by the C18A/C138A double mutant. Hence, the 18-138 disulfide bond is not essential for angiotensinogen production, but is required for the correct folding of the molecule. The mutation of Cys 232 to Ala (C232A mutant) drastically reduced the production of the mutant protein by COS-7 and CHO-K1 (data not shown) cells, but only when there was a Met at position 235. The C232A mutant was normally produced when there was a Thr at position 235 (C232A/M235T double mutant). These results suggest that an interaction between amino acid residues 232 and 235 is important for angiotensinogen production in eucaryotic cells.
Role of Cys 232 in the Angiotensinogen⅐proMBP Complex
Since human angiotensinogen contains free cysteines and a disulfide bridge between Cys 18 and Cys
138
, then Cys 232 and Cys 308 are likely to be free. We identified the residue involved in the formation of the angiotensinogen⅐proMBP complex by producing this complex in vitro using two CHO cell lines, one producing wild-type angiotensinogen and the other proMBP in co-culture (10% CHO cells producing wild-type angiotensinogen and 90% CHO cells producing proMBP). This produced a large amount of angiotensinogen⅐proMBP complex with a minimum of monomeric angiotensinogen. The angiotensinogen⅐proMBP complex was analyzed by Western blotting (Fig. 4) , under non-reducing (Ϫ␤-mercaptoethanol) and reducing conditions (ϩ␤-mercaptoethanol). The HCL antibody detected a shift from a monomeric form (60 kDa) to a high molecular mass form (200 kDa) under non-reducing conditions. The usual monomeric form was detected with ␤-mercaptoethanol (Fig. 4, upper) . As reported by Oxvig et al. (18) , the complex was not detected by the J163-15E antibody without reduction because the proMBP epitope was hidden, but was detected after reduction as several bands between 50 and 90 kDa, due to the extremely heterogeneous glycosylation of recombinant proMBP previously characterized in Ref. 34 (Fig. 4, lower) .
We have also transiently co-transfected COS-7 cells with wild-type hAGT cDNA or different cysteine mutant hAGT cDNAs and MBP cDNA. Western blot analysis showed that co-transfection of COS-7 cells with MBP cDNA plus various mutants of hAGT caused a shift from the monomeric to the complex form that was proportional to the number of COS-7 cells transfected, except for the C232A/M235T mutant in which Cys 232 is mutated to Ala. The complex was poorly stained because less than 30% of the COS-7 cells produced the two co-transfected proteins, but it was clearly absent from the co-transfection experiment using C232A/M235T hAGT and MBP cDNAs (Fig. 5A) . These data were confirmed by transfecting a CHO cell line overproducing C232A/M235T mutant angiotensinogen with MBP cDNA. The wild-type angiotensinogen produced by the CHO cells gave 3 molecular species of around 60, 120, and 180 kDa on 9% SDS-PAGE under non-reducing conditions. Transfection with MBP cDNA caused the production, by the 30% of CHO cells transfected, of an extra 200-kDa band, which corresponded to angiotensinogen⅐proMBP complex. This 200-kDa form did not appear after co-transfection of CHO cells producing the C232A/M235T mutant (Fig. 5B) . Finally, a large quantity of complex form, readily detected by Western blot analysis, was produced by co-culture. CHO cells producing proMBP (90%) plated with CHO cells producing C232A/M235T mutant angiotensinogen (10%) produced no complex (Fig. 5C ). Hence Cys 232 is the only angiotensinogen cysteine that forms a disulfide bond with one of the proMBP cysteines.
Function of the Angiotensinogen⅐proMBP Complex
Renin Hydrolysis of the Angiotensinogen⅐proMBP ComplexAngiotensinogen⅐proMBP complex was produced by co-culture and isolated on a Superose 12 column. Each fraction was analyzed for its angiotensinogen content by enzymatic assay and Western blotting. Two peaks of Ang I were generated with an apparent molecular mass of 200 and 60 kDa after migration on SDS-PAGE. proMBP was present in the 200-kDa peak since this peak was not produced when untransfected CHO cells replaced proMBP-producing cells (data not shown). The rate of Ang I production from angiotensinogen⅐proMBP complex was studied using increasing amounts of renin. The human renin concentration required for a maximal Ang I production was 1.25 nM for the monomeric form and 12.5 nM for the complex (Fig. 6A) . The initial velocity of angiotensinogen hydrolysis by renin was 1.12 Ϯ 0.05 ng of Ang I/h for monomeric angio- 
FIG. 2. Function of reduced purified angiotensinogen.
A, Western blot of unreduced and reduced purified human recombinant angiotensinogen (250 ng) using anti-Ang I polyclonal antibody N1345. Purified recombinant angiotensinogen was reduced with 10 Ϫ2 -10 mM DTT and alkylated with 10 mM iodoacetic acid (IAc). B, Ang I generation after exhaustive cleavage of reduced angiotensinogen by incubation with 1.25 nM recombinant renin at pH 5.7 during 1 h. Data are expressed as the ratio of Ang I generated by reduced and unreduced alkylated angiotensinogen. Data are the mean Ϯ range of two independent determinations. tensinogen and 7.65 Ϯ 0.15 ng of Ang I/h for the complex (Fig.  6B) . The same results were obtained whether there was a Met or a Thr residue in position 235 (data not shown).
Influence of M235T Genotype on Angiotensinogen⅐proMBP Complex Formation-The influence of the M235T angiotensinogen polymorphism on the amount of complex was examined using Met  235 angiotensinogen⅐proMBP and Thr   235 angiotensinogen⅐proMBP, isolated by molecular sieving. The area under the curves of Ang I generated by the 200-and 60-kDa peaks differed according to the M235T variant (Fig. 7,  A and B) . Two independent experiments gave the same results: the high molecular weight form accounted for 71.9% Ϯ 3.5 of the total area under the curve with Met 235 angiotensinogen and for only 57.7% Ϯ 2.8 with Thr 235 angiotensinogen.
DISCUSSION
Cysteine residues have important effects on the properties, structure, and function of proteins (35) . Disulfide bridges contribute to the structure and stability of native proteins (36) whereas the sulfhydryl groups of free cysteine residues are highly reactive, are readily oxidized (37) , and are involved in the formation of multimeric complexes via covalent disulfide bonds (38) . Because angiotensinogen is a key protein of the renin-angiotensin system and because hAGT polymorphisms have been associated with hypertension, we have examined the roles of its four cysteine residues. We have shown that each cysteine has a specific function, Cys 18 and Cys 138 are linked by a disulfide bridge, Cys 232 forms a covalent bond with proMBP, and Cys 308 probably forms a covalent link with another angiotensinogen molecule.
The location of the disulfide bridge was not totally unexpected because Cys 18 and Cys 138 are highly conserved among mammalian species (19 -22) . We located the disulfide bridge in the fully N-deglycosylated mutant because of the heterogeneity of the wild-type protein due to glycosylation (24) . The 18-138 disulfide bond was clearly established by mass spectrometry. Analysis of the cysteine mutants was in accordance with a single 18-138 disulfide bridge in the wild-type protein, in which free cysteines were labeled with iodo[ . The mutation of Cys 138 to Ala and the double mutation C18A/C138A caused an additional band which appeared under non-reducing SDS-PAGE; this band could correspond to a differently folded molecule with an alternative disulfide bridge or to a different glycosylated protein with an abnormal glycosylation of Asn 138 . The triple mutant C18A/C138A/C308A was also normally produced. The production of these mutants showed that the disulfide bridge is not required for production of the protein, as with other proteins like phospholipase A 2 (39) , although it is required for N-glycosylation of Asn 14 . We also showed that the presence of this disulfide bond allows the NH 2 terminus of angiotensinogen, which is Ang I, to adopt a specific conformation, and consequently may protect it against an unspecific aminoterminal degradation. This was shown by the lack of recognition of pure wild-type recombinant angiotensinogen by anti-Ang I antibody in non-reducing conditions and by its recognition by the same antibody after complete reduction of the disulfide bridge or after the mutation of Cys 18 and Cys 138 in C18A/ C138A and C18A/C138A/C308A mutants (data not shown). 
Cys
232 is specific to human species and is located close to the M235T site. It is crucial for protein folding and for formation of angiotensinogen⅐proMBP complex. The amino acids at position 232 and 235 seem to interact. The mutation of Cys 232 to Ala in the wild-type protein (Met 235 ) drastically decreases angiotensinogen production, whereas the same mutation in the Thr 235 angiotensinogen (C232A/M235T mutant) has little effect. Although the tertiary structure of angiotensinogen is not known, the region around residue 235 is probably at the surface of the protein. Cohen et al. (40) have shown that an anti-human angiotensinogen monoclonal antibody can detect the M235T angiotensinogen genotype, which causes a significant change in its epitope. Cys 232 is also near the surface and could be easily accessible to oxidation in the wild-type protein.
The Met 235 in the C232A mutant, which lacks Cys 232 , may be sulfoxidated. This methionine oxidation could cause a conformational change, leading to abnormal folding of the molecule and rapid intracellular degradation. Methionine oxidation can cause a loss or gain of function in several proteins and can have pathophysiological significance (reviewed in Ref. 41) .
HMW angiotensinogen has been detected in plasma especially during pregnancy, when it can account for up to 70% of the angiotensinogen in the amniotic fluid (10) . This HMW form has a wide range of molecular mass by gel filtration (200 -500 kDa) and can generate Ang I (reviewed in Ref. 8). Oxvig et al. (18) purified a 2:2 angiotensinogen⅐proMBP complex from pooled plasma from pregnant women. We used a co-culture of CHO cells producing human angiotensinogen and proMBP to show the formation of a complex between angiotensinogen and proMBP in vitro. The complex is spontaneously formed in the culture medium, revealing a highly degree of interaction between angiotensinogen and proMBP. It is detected by Western blotting with specific antibodies and has the same molecular weight as the angiotensinogen⅐proMBP complex purified by Oxvig (18) . We also find no complex after reduction, confirming that a disulfide bridge links the two proteins. Site-directed mutagenesis demonstrated that Cys 232 is the only cysteine in angiotensinogen that forms a covalent bond with one of the 12 cysteines of proMBP (29) . Studies with the partially purified angiotensinogen⅐proMBP complex indicated that the complex is not efficiently hydrolyzed by human renin, since the renin concentration required to generate Ang I is 10 times higher than for the monomeric form. The initial velocity of angiotensinogen⅐proMBP hydrolysis by renin is 7 times slower than for monomeric form. Therefore angiotensinogen⅐proMBP complex could be a storage form of angiotensinogen, especially during pregnancy. This is in agreement with the study of pregnancy-associated plasma protein⅐proMBP complex by Haaning et al. (42) , who suggested that proMBP inhibits proteolytic activity of pregnancy-associated plasma protein by shielding its active site. The questions raised by the in vitro data are the contribution of the angiotensinogen⅐proMBP complex in HMW angiotensinogen and its physiological role. Specific methods of measurement will be needed to identify angiotensinogen⅐proMBP complex and to study its function in vivo.
The angiotensinogen M235T polymorphism seems to influence the respective percentage of monomeric angiotensinogen and angiotensinogen⅐proMBP complex rather than the kinetic parameters. Angiotensinogen has been implicated in essential hypertension and also in pregnancy-induced hypertension. The M235T polymorphism alone does not alter the K m for renin (43) and has been considered up to now to be a simple genetic marker of a causative variant possibly located in the promoter region of the gene (4). Our findings could place this polymorphism in a different perspective, by showing that it could have a direct influence on the function of angiotensinogen. Our data suggest that, during pregnancy and for a given level of angiotensinogen, more angiotensinogen⅐proMBP complex is formed in MM subjects compared with TT subjects. Since Ang I is less efficiently cleaved from angiotensinogen⅐proMBP complex, its production could be significantly lower in women bearing the Met 235 allele. If these data are confirmed in vivo, they could provide a physiological explanation for the genetic association between M235T angiotensinogen polymorphism and pregnancy-induced hypertension.
The ability of human angiotensinogen to form a covalent complex and the presence of a reactive cysteine at position 232 raises new and important questions. Angiotensinogen has long been known to be an acute-phase protein (44, 45) and angiotensinogen transcription is increased by cytokines (for review, see Ref. 46 ). By complexing with proteins other than proMBP through its Cys 232 , angiotensinogen could have an anti-inflammatory function, distinct from a serine protease inhibitor activity. It is therefore important to search for angiotensinogen partners other than proMBP.
